Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: An open-label, multicentre, randomised, controlled study

Journal of Family Planning and Reproductive Health Care

Volumn 38, Issue 2, 2012, Pages 73-83

  Klipping, Christine ^a   Duijkers, Ingrid ^a   Fortier, Michel P ^b   Marr, Joachim ^c   Trummer, Dietmar ^c   Elliesen, Jörg ^c  

^a Dinox BV   (Netherlands)

^b Clinique de Recherche en Santédes Femmes   (Canada)

^c BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; ANDROSTANE DERIVATIVE; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MENSTRUAL CYCLE; MENSTRUATION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; SPOTTING; TREATMENT OUTCOME; ADOLESCENT; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; METRORRHAGIA; YOUNG ADULT;

ADOLESCENT; ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; ETHINYL ESTRADIOL; FEMALE; HUMANS; METRORRHAGIA; YOUNG ADULT;

EID: 84860760517     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1136/jfprhc-2011-100213     Document Type: Article

References (22)

1. Klipping C, Duijkers I, Trummer D, et al. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008;78:16-25.
2. Szarewski A. Sisters doing it for themselves. J Fam Plann Reprod Health Care 2009;35:71-72.
3. Rutter W, Knight C, Vizzard J, et al. Women's attitudes to withdrawal bleeding and their knowledge and beliefs about the oral contraceptive pill. Med J Aust 1988;149:417-419.
4. den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999;59:357-362. (Pubitemid 29430163)
5. Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 2001;98:771-778. (Pubitemid 33042543)
6. Glasier AF, Smith KB, van der Spuy ZM, et al. Amenorrhea associated with contraception - an international study on acceptability. Contraception 2003;67:1-8. (Pubitemid 36084280)
7. Wiegratz I, Hommel HH, Zimmermann T, et al. Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 2004;69:37-42. (Pubitemid 38076964)
8. Andrist LC, Arias RD, Nucatola D, et al. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception 2004;70:359-363. (Pubitemid 39422511)
9. Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 2006;73:229-234. (Pubitemid 43202171)
10. Archer DF, Jensen JT, Johnson JV, et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006;74:439-445. (Pubitemid 46037535)
11. Kroll R, Reape KZ, Margolis M. The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol. Contraception 2010;81:41-48.
12. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003;68:89-96. (Pubitemid 37101032)
13. Kwiecien M, Edelman A, Nichols MD, et al. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 2003;67:9-13. (Pubitemid 36084281)
14. Legro RS, Pauli JG, Kunselman AR, et al. Effects of continuous versus cyclical oral contraception: a randomized controlled trial. J Clin Endocrinol Metab 2008;93:420-429. (Pubitemid 351240811)
15. Anttila L, Kunz M, Marr J. Contraceptive efficacy of a combined oral contraceptive containing ethinylestradiol 20 mcg/drospirenone 3 mg administered in 24/4 regimen: a pooled analysis of four, open-label studies. Int J Gynecol Obstet 2009;107:s622.
16. Bachmann G, Sulak PJ, Sampson-Landers C, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception 2004;70:191-198. (Pubitemid 39119980)
17. Hernádi L, Marr J, Trummer D, et al. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen. Contraception 2009;80:18-24.
18. Klipping C, Duijkers I, Fortier MP, et al. Long-term tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study. J Fam Plann Reprod Health Care 2012;38:84-93.
19. Ferrero S, Abbamonte LH, Giordano M, et al. What is the desired menstrual frequency of women without menstruationrelated symptoms? Contraception 2006;73:537-541.
20. Palacios S, Wildt L, Parke S, et al. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol 2010;149:57-62.
21. Brucker C, Hedon B, The HS, et al. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen. Contraception 2010;81:501-509.
22. Endrikat J, Müller U, Düsterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 1997;55:131-137. (Pubitemid 27180387)